Report cover image

Global Gabapentin Drug Market Growth 2025-2031

Published Oct 14, 2025
Length 153 Pages
SKU # LPI20470130

Description

The global Gabapentin Drug market size is predicted to grow from US$ 1674 million in 2025 to US$ 2086 million in 2031; it is expected to grow at a CAGR of 3.7% from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Gabapentin is a medication used to treat epilepsy, neuropathic pain, hot flashes, and restless legs syndrome. In epilepsy, it may be used for those with partial seizures. It is recommended as one of a number of first line medications for the treatment of neuropathic pain in diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LP Information, Inc. (LPI) ' newest research report, the “Gabapentin Drug Industry Forecast” looks at past sales and reviews total world Gabapentin Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Gabapentin Drug sales for 2025 through 2031. With Gabapentin Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gabapentin Drug industry.

This Insight Report provides a comprehensive analysis of the global Gabapentin Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Gabapentin Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gabapentin Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gabapentin Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gabapentin Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Gabapentin Drug market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Capsule
Tablet
Oral Solution

Segmentation by Application:
Postherpetic Neuralgia in Adults
Partial Onset Seizures
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Pfizer
Depomed
Apotex
Teva
Acella Pharmaceuticals
Taro
Sun Pharmaceutical
Glenmark
Amneal Pharmaceuticals
Aurobindo Pharma
Zydus Pharmaceuticals
Hi-Tech Pharmaceuticals
Marksans Pharma
Mylan
InvaGen Pharmaceuticals
Alkem Laboratories
Tris Pharma
ACI HealthCare Limited
Jiangsu Hengrui Medicine
CSPC Ouyi Pharmaceutical
Sciegen Pharmaceuticals
Epic Pharma
Lupin Limited

Key Questions Addressed in this Report

What is the 10-year outlook for the global Gabapentin Drug market?

What factors are driving Gabapentin Drug market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Gabapentin Drug market opportunities vary by end market size?

How does Gabapentin Drug break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.

Table of Contents

153 Pages
*This is a tentative TOC and the final deliverable is subject to change.*
1 Scope of the Report
2 Executive Summary
3 Global by Company
4 World Historic Review for Gabapentin Drug by Geographic Region
5 Americas
6 APAC
7 Europe
8 Middle East & Africa
9 Market Drivers, Challenges and Trends
10 Manufacturing Cost Structure Analysis
11 Marketing, Distributors and Customer
12 World Forecast Review for Gabapentin Drug by Geographic Region
13 Key Players Analysis
14 Research Findings and Conclusion
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.